Richard E Kuntz

Author PubWeight™ 131.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 13.29
2 Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004 12.58
3 Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation 2010 2.88
4 The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004 2.78
5 A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005 2.56
6 Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002 2.53
7 Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004 2.35
8 Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004 2.28
9 The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: a systematic review. J Rehabil Med 2013 2.20
10 Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006 2.16
11 Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol 2004 2.05
12 Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation 2003 2.04
13 Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation 2004 1.96
14 Medical device development: from prototype to regulatory approval. Circulation 2004 1.90
15 Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004 1.83
16 Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004 1.72
17 Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005 1.67
18 Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002 1.62
19 Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006 1.62
20 Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002 1.61
21 Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv 2003 1.61
22 Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation 2008 1.59
23 A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation 2002 1.58
24 Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006 1.56
25 Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation 2004 1.54
26 Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004 1.53
27 Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 2004 1.52
28 Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002 1.51
29 Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation 2004 1.49
30 Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation 2002 1.48
31 Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int 2008 1.44
32 Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 2005 1.43
33 Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J 2006 1.42
34 The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv 2007 1.38
35 Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol 2003 1.29
36 Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003 1.27
37 Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003 1.20
38 Reproducibility of coronary lumen, plaque, and vessel wall reconstruction and of endothelial shear stress measurements in vivo in humans. Catheter Cardiovasc Interv 2003 1.20
39 Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004 1.20
40 Network news: powering clinical research. Sci Transl Med 2013 1.19
41 Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006 1.18
42 Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007 1.14
43 The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006 1.13
44 Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 2002 1.11
45 Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005 1.10
46 Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation 2002 1.08
47 Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005 1.04
48 Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 2004 1.02
49 Regions of low endothelial shear stress are the sites where coronary plaque progresses and vascular remodelling occurs in humans: an in vivo serial study. Eur Heart J 2007 1.02
50 Remodeling characteristics of minimally diseased coronary arteries are consistent along the length of the artery. Am J Cardiol 2005 1.02
51 Risk assessment for percutaneous coronary intervention: our version of the weather report? J Am Coll Cardiol 2003 1.01
52 Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005 1.00
53 Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 2006 0.92
54 The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency. Ann Intern Med 2013 0.91
55 ACC/AHA 2007 methodology for the development of clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol 2007 0.89
56 First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005 0.88
57 Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation 2004 0.87
58 Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 2006 0.87
59 Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005 0.85
60 Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J 2006 0.84
61 Risks of coronary artery bypass surgery in dialysis-dependent patients--analysis of the 2001 National Inpatient Sample. Nephrol Dial Transplant 2007 0.84
62 Sample size calculation for a historically controlled clinical trial with adjustment for covariates. J Biopharm Stat 2002 0.83
63 Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J 2003 0.83
64 Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006 0.83
65 Utility of the Safe-Cross-guided radiofrequency total occlusion crossing system in chronic coronary total occlusions (results from the Guided Radio Frequency Energy Ablation of Total Occlusions Registry Study). Am J Cardiol 2004 0.82
66 Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007 0.82
67 Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 2004 0.82
68 Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol 2002 0.82
69 A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis. Heart Vessels 2006 0.81
70 Humanitarian Use Devices/Humanitarian Device Exemptions in cardiovascular medicine. Circulation 2005 0.81
71 Understanding the drug-eluting stent trials. Am J Cardiol 2007 0.80
72 Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol 2002 0.80
73 Feasibility trial of carotid stenting with and without an embolus protection device. J Endovasc Ther 2005 0.80
74 Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol 2007 0.79
75 Measuring percutaneous coronary intervention quality by simple case volume. Circulation 2005 0.79
76 Coronary drug-eluting stent development: issues in trial design. Am Heart J 2005 0.79
77 Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol 2003 0.79
78 The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). Am J Cardiol 2006 0.78
79 Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 2007 0.78
80 Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002 0.78
81 Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol 2006 0.77
82 Treatment of coronary stent thrombosis with rheolytic thrombectomy: results from a multicenter experience. Catheter Cardiovasc Interv 2003 0.77
83 Two-year clinical follow-up of 90Sr/90 Y beta-radiation versus placebo control for the treatment of in-stent restenosis. Am Heart J 2005 0.77
84 Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005 0.77
85 ACC/AHA 2007 methodology for the development of clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation 2007 0.77
86 Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007 0.76
87 Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? Am Heart J 2005 0.75
88 Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting. Am J Cardiol 2005 0.75
89 Letter by Kereiakes et al regarding article, "Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern". Circulation 2007 0.75
90 Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. J Nephrol 2006 0.75
91 Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: results from the multicenter X-Sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study. Catheter Cardiovasc Interv 2003 0.75
92 Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site. Am Heart J 2011 0.75
93 The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol 2002 0.75
94 Application of models for multivariate mixed outcomes to medical device trials: coronary artery stenting. Stat Med 2003 0.75
95 Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction. Am Heart J 2010 0.75
96 Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry. Int J Radiat Oncol Biol Phys 2002 0.75
97 Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention 2006 0.75